BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML

Reuters

02 Dec 2024

BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML

Dec 2 (Reuters) - Senti Biosciences SNTI.O:

SENTI BIO ANNOUNCES POSITIVE INITIAL CLINICAL DATA IN PHASE 1 CLINICAL TRIAL OF SENTI-202, A LOGIC GATED, SELECTIVE CD33/FLT3-TARGETING CAR-NK CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING AML
SENTI BIOSCIENCES INC - SENTI-202 GENERALLY WELL-TOLERATED WITH CONSISTENT ADVERSE EVENT PROFILE
SENTI BIOSCIENCES INC - DOSE ESCALATION CONTINUING, ADDITIONAL DATA EXPECTED IN 2025

Source text: ID:nGNX4XG7dt

Further company coverage: SNTI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2488673216"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488673216\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2488673216?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-02 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488673216","market":"us","top_or_hot":-1,"title":"BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML</title></head><body><p><span>Dec 2 (Reuters)</span><span> - </span>Senti Biosciences <span>SNTI.O</span>:</p><ul><li><p>SENTI BIO ANNOUNCES POSITIVE INITIAL CLINICAL DATA IN PHASE 1 CLINICAL TRIAL OF SENTI-202, A LOGIC GATED, SELECTIVE CD33/FLT3-TARGETING CAR-NK CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING AML</p></li><li><p>SENTI BIOSCIENCES INC - SENTI-202 GENERALLY WELL-TOLERATED WITH CONSISTENT ADVERSE EVENT PROFILE</p></li><li><p>SENTI BIOSCIENCES INC - DOSE ESCALATION CONTINUING, ADDITIONAL DATA EXPECTED IN 2025</p></li></ul><p>Source text: <span>ID:nGNX4XG7dt</span></p><p>Further company coverage: <span>SNTI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-02 20:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AML</title></head><body><p><span>Dec 2 (Reuters)</span><span> - </span>Senti Biosciences <span>SNTI.O</span>:</p><ul><li><p>SENTI BIO ANNOUNCES POSITIVE INITIAL CLINICAL DATA IN PHASE 1 CLINICAL TRIAL OF SENTI-202, A LOGIC GATED, SELECTIVE CD33/FLT3-TARGETING CAR-NK CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING AML</p></li><li><p>SENTI BIOSCIENCES INC - SENTI-202 GENERALLY WELL-TOLERATED WITH CONSISTENT ADVERSE EVENT PROFILE</p></li><li><p>SENTI BIOSCIENCES INC - DOSE ESCALATION CONTINUING, ADDITIONAL DATA EXPECTED IN 2025</p></li></ul><p>Source text: <span>ID:nGNX4XG7dt</span></p><p>Further company coverage: <span>SNTI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNTI","symbol_name":"Senti Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUA5H5M4H:1","article_id":"2488673216","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488673216","pubTimestamp":1733142302,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refracto","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNTI":"Senti Biosciences, Inc.","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"BRIEF-Senti Bio宣布SENTI-202 1期临床试验的积极初始临床数据，Senti-202是一种逻辑门控、选择性CD33/FLT3靶向CAR-NK细胞疗法，用于治疗包括AML在内的复发/难治性血液恶性肿瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNTI":0.9},"content_text":"BRIEF-Senti Bio Announces Positive Initial Clinical Data In Phase 1 Clinical Trial Of Senti-202, A Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy For The Treatment Of Relapsed/Refractory Hematologic Malignancies Including AMLDec 2 (Reuters) - Senti Biosciences SNTI.O:SENTI BIO ANNOUNCES POSITIVE INITIAL CLINICAL DATA IN PHASE 1 CLINICAL TRIAL OF SENTI-202, A LOGIC GATED, SELECTIVE CD33/FLT3-TARGETING CAR-NK CELL THERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES INCLUDING AMLSENTI BIOSCIENCES INC - SENTI-202 GENERALLY WELL-TOLERATED WITH CONSISTENT ADVERSE EVENT PROFILESENTI BIOSCIENCES INC - DOSE ESCALATION CONTINUING, ADDITIONAL DATA EXPECTED IN 2025Source text: ID:nGNX4XG7dtFurther company coverage: SNTI.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}